Literature DB >> 28196977

Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus.

Fumiaki Tabuchi1, Yasuhiko Matsumoto1,2, Masaki Ishii1, Keita Tatsuno3, Mitsuhiro Okazaki4, Tomoaki Sato3, Kyoji Moriya3, Kazuhisa Sekimizu1,2.   

Abstract

We previously reported isolating vancomycin (VAN) highly resistant Staphylococcus aureus (VRSA) strains from clinical methicillin-resistant S. aureus strains by repeating steps of in vitro mutagenesis and VAN selection. Here we describe that the in vitro susceptibility of these VRSA strains to VAN was markedly increased by combined treatment with β-lactams such as ceftriaxone and oxacillin. Furthermore, in an in vivo silkworm infection model with VRSA, a combination of VAN and ceftriaxone exhibited therapeutic effects, whereas a combination of VAN and oxacillin did not. These findings suggest that combining VAN with an appropriate β-lactam, such as ceftriaxone, is therapeutically effective against infectious diseases caused by VRSA.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28196977     DOI： 10.1038/ja.2017.7

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  40 in total

1.  First case of infection with vancomycin-resistant Staphylococcus aureus in Europe.

Authors:  José Melo-Cristino; Cristina Resina; Viviana Manuel; Luís Lito; Mário Ramirez
Journal:  Lancet       Date:  2013-06-21       Impact factor: 79.321

2.  Drug discovery and development focusing on existing medicines: drug re-profiling strategy.

Authors:  Tohru Mizushima
Journal:  J Biochem       Date:  2011-03-24       Impact factor: 3.387

3.  In vitro and in vivo anti-MRSA activities of nosokomycins.

Authors:  Ryuji Uchida; Hideaki Hanaki; Hidenori Matsui; Hiroshi Hamamoto; Kazuhisa Sekimizu; Masato Iwatsuki; Yong Pil Kim; Hiroshi Tomoda
Journal:  Drug Discov Ther       Date:  2014-12

4.  Therapeutic effects of three trichothecenes in the silkworm infection assay with Candida albicans.

Authors:  Ryuji Uchida; Shingo Namiguchi; Hiroyuki Ishijima; Hiroshi Tomoda
Journal:  Drug Discov Ther       Date:  2016-02

5.  Trimethoprim, a sulphonamide potentiator.

Authors:  S R Bushby; G H Hitchings
Journal:  Br J Pharmacol Chemother       Date:  1968-05

6.  Nosokomycins, new antibiotics discovered in an in vivo-mimic infection model using silkworm larvae. II: Structure elucidation.

Authors:  Ryuji Uchida; Masato Iwatsuki; Yong-Pil Kim; Satoshi Omura; Hiroshi Tomoda
Journal:  J Antibiot (Tokyo)       Date:  2010-03-05       Impact factor: 2.649

7.  Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides.

Authors:  Alejandro Domenech; Sandra Ribes; Carmen Cabellos; Ferran Taberner; Fe Tubau; M Angeles Domínguez; Abelardo Montero; Josefina Liñares; Javier Ariza; Francesc Gudiol
Journal:  J Antimicrob Chemother       Date:  2005-08-24       Impact factor: 5.790

8.  Expression and inducibility in Staphylococcus aureus of the mecA gene, which encodes a methicillin-resistant S. aureus-specific penicillin-binding protein.

Authors:  K Ubukata; R Nonoguchi; M Matsuhashi; M Konno
Journal:  J Bacteriol       Date:  1989-05       Impact factor: 3.490

9.  Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

Authors:  B J Werth; C Vidaillac; K P Murray; K L Newton; G Sakoulas; P Nonejuie; J Pogliano; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

10.  Effect of combination of oxacillin and non-beta-lactam antibiotics on methicillin-resistant Staphylococcus aureus.

Authors:  H Komatsuzawa; J Suzuki; M Sugai; Y Miyake; H Suginaka
Journal:  J Antimicrob Chemother       Date:  1994-06       Impact factor: 5.790
View more
  6 in total

1.  In vitro antagonistic inhibitory effects of palm seed crude oils and their main constituent, lauric acid, with oxacillin in Staphylococcus aureus.

Authors:  Klara Lalouckova; Eva Skrivanova; Johana Rondevaldova; Adela Frankova; Josef Soukup; Ladislav Kokoska
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

2.  D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus.

Authors:  Fumiaki Tabuchi; Yasuhiko Matsumoto; Masaki Ishii; Keita Tatsuno; Mitsuhiro Okazaki; Tomoaki Sato; Kyoji Moriya; Kazuhisa Sekimizu
Journal:  J Antibiot (Tokyo)       Date:  2017-06-07       Impact factor: 2.649

Review 3.  Advantages of the Silkworm As an Animal Model for Developing Novel Antimicrobial Agents.

Authors:  Suresh Panthee; Atmika Paudel; Hiroshi Hamamoto; Kazuhisa Sekimizu
Journal:  Front Microbiol       Date:  2017-03-07       Impact factor: 5.640

4.  Evidence from an In Vitro Study: Is Oxacillin Plus Vancomycin a Better Choice for Heteroresistant Vancomycin-Intermediate Staphylococcus aureus?

Authors:  Yamuna Devi Bakthavatchalam; Ravikar Ralph; Balaji Veeraraghavan; Priyanka Babu; Elakkiya Munusamy
Journal:  Infect Dis Ther       Date:  2018-11-21

5.  A Bombyx mori Infection Model for Screening Antibiotics against Staphylococcus epidermidis.

Authors:  Aurora Montali; Francesca Berini; Alessio Saviane; Silvia Cappellozza; Flavia Marinelli; Gianluca Tettamanti
Journal:  Insects       Date:  2022-08-19       Impact factor: 3.139

6.  In Vitro activity of novel glycopolymer against clinical isolates of multidrug-resistant Staphylococcus aureus.

Authors:  Vidya P Narayanaswamy; Scott A Giatpaiboon; John Uhrig; Paul Orwin; William Wiesmann; Shenda M Baker; Stacy M Townsend
Journal:  PLoS One       Date:  2018-01-17       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.